Name | Title | Contact Details |
---|---|---|
Rebecca Helm |
Director of People and Culture | Profile |
Amy Hutchins |
Chief Marketing Officer | Profile |
Calm - Apple`s 2017 iPhone App of the Year! Our mission is to make the world happier and healthier through the superpower of Calm.
Health Dialog is a total population healthcare services provider that offers risk-bearing entities (health plans, employers, and providers) an integrated suite of services driven by powerful analytics. These services include member engagement programs, multi-channel health coaching, medication adherence support, and shared decision making tools. We are part of the Rite Aid family. Through client partnerships and customized engagements, our dedicated team of healthcare professionals helps clients improve quality of care and reduce healthcare costs while empowering individuals to make informed health and wellness decisions.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
Thornhill Research Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Wisdo is an award-winning social health and clinical referral platform that addresses the adverse consequences of social isolation and loneliness on the mental and physical health of 124 million Americans. Research shows that Wisdo results in $1,900+ in annual medical cost savings, a 37% reduction in depression, a 34% increase in the number of healthy days experienced by our members, and an 80% retention rate on month 12. More than 1 million adults have joined the Wisdo community, where they realized measurable improvements in their health through community-driven social support, professionally moderated group sessions, and when appropriate clinical referrals based on predictive analytics.